Drug Profile
Herpes simplex vaccine live - AVANT
Alternative Names: dl5-29Latest Information Update: 11 Apr 2005
Price :
$50
*
At a glance
- Originator Harvard Medical School
- Developer AVANT Immunotherapeutics; Harvard Medical School
- Class Viral vaccines; Viruses
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Herpes simplex virus infections
Most Recent Events
- 11 Apr 2005 Discontinued - Preclinical for Herpes simplex virus infections in USA (unspecified route)
- 12 Jan 2004 No development reported - Preclinical for Herpes simplex virus infections in USA (unspecified route)
- 06 Dec 2000 AVANT has been awarded a 1-year $US220 000 SBIR grant from the NIH for development of dl5-29